News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiogen Pharma's New Anti-Anxiety Drug Starts A Clinical Phase II In Generalized Anxiety Disorders In Vienna



7/5/2006 1:26:12 PM

PISA, Italy--(BUSINESS WIRE)--July 5, 2006--Abiogen Pharma today announced the start of a Phase II clinical trial in Vienna (Austria) in patients affected by GAD with ABIO 08/01, a new anti-anxiety drug. ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives, and is being developed to treat clinical anxiety states such as panic disorder or GAD.

Read at press release


comments powered by Disqus
   
Anxiety

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES